Get the Stockscreener App
0.684
3.66%
-0.026
Unicycive Therapeutics Inc stock is traded at $0.684, with a volume of 1.30M.
It is down -3.66% in the last 24 hours and up +34.28% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
See More
Previous Close:
$0.71
Open:
$0.72
24h Volume:
1.30M
Relative Volume:
0.81
Market Cap:
$71.00M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.3455
EPS:
-1.98
Net Cash Flow:
$-18.30M
1W Performance:
-4.27%
1M Performance:
+34.28%
6M Performance:
+8.57%
1Y Performance:
+19.00%
1-Day Range:
$0.68
$0.744
1-Week Range:
$0.6201
$0.744
52-Week Range:
$0.202
$1.818
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.684 | 71.00M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics - The Manila Times
Unicycive Therapeutics Announces Publication of - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) Head-To-Head Review - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Decline in Short Interest - MarketBeat
Unicycive Therapeutics Inc (NASDAQ: UNCY): Overvalued In Comparison To Others? - Stocks Register
Analyzing Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) - Defense World
We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely - Simply Wall St
5,000,000 Shares in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Purchased by Walleye Capital LLC - MarketBeat
Acuta Capital Partners LLC Takes $807,000 Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Yahoo Finance
Great Point Partners LLC Takes $3.49 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - MarketBeat
Unicycive's SWOT analysis: CKD treatment innovator's stock faces pivotal year - Investing.com India
Unicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46 - MSN
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Speculative Buy" Rating from Benchmark - MarketBeat
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Unicycive Therapeutics to Participate in Two Upcoming - GlobeNewswire
Unicycive Therapeutics CEO to Present at Noble Capital and Piper Sandler Healthcare Conferences | UNCY Stock News - StockTitan
Logos Global Management LP Adjusts Stake in Unicycive Therapeuti - GuruFocus.com
RA Capital Management's Strategic Acquisition of Unicycive Thera - GuruFocus.com
Great Point Partners LLC's Strategic Investment in Unicycive The - GuruFocus.com
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc - GuruFocus.com
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Unicycive's OLC Drug Gets FDA Review Date, Reports Strong Q3 Pipeline Progress | UNCY Stock News - StockTitan
USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate - Medical Dialogues
Unicycive Therapeutics (NASDAQ:UNCY) Given Buy Rating at HC Wainwright - MarketBeat
Unicycive shares hold as FDA accepts NDA for kidney treatment By Investing.com - Investing.com UK
Shilpa Medicare update on its CDMO partnerUnicycive Therapeutics - Business Standard
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Marketscreener.com
Unicycive eyes June FDA verdict for hyperphosphataemia drug - pharmaphorum
Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia - MarketWatch
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The Manila Times
Unicycive Therapeutics Announces U.S. FDA Acceptance of the - GlobeNewswire
Unicycive's Kidney Disease Drug Gets FDA Review Date, Aims for 2025 Launch | UNCY Stock News - StockTitan
Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com
Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - The Manila Times
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St
A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News
Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex
Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa
UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance
Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):